Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia

Efficacy and Safety of IV-to-Oral Lefamulin, a Pleuromutilin Antibiotic, for Treatment of Community-Acquired Bacterial Pneumonia: The Phase 3 LEAP 1 Trial

(2019) Thomas M File et al.   CLINICAL INFECTIOUS DISEASES

Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015–2016 and Characterization of Resistance Mechanisms

(2019) Rodrigo E. Mendes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin

(2019) Keith A Rodvold   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia

(2019) Sujata M Bhavnani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae

(2019) Wolfgang W Wicha et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model

(2019) Wolfgang W Wicha et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America

(2019) Joshua P. Metlay et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens

(2018) Susanne Paukner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States

(2016) Rodrigo E. Mendes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid

(2016) M. Zeitlinger et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism

(2016) Zohar Eyal et al.   Scientific Reports

Population Pharmacokinetic Analyses for BC-3781 Using Phase 2 Data from Patients with Acute Bacterial Skin and Skin Structure Infections

(2014) C. M. Rubino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase II Clinical Study of BC-3781, a Pleuromutilin Antibiotic, in Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections

(2013) W. T. Prince et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activity of the Pleuromutilin Antibiotic BC-3781 against Bacterial Pathogens Isolated in the SENTRY Antimicrobial Surveillance Program in 2010

(2013) Susanne Paukner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)

(2012) H. S. Sader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY